Trial Profile
A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary) ; Fluorouracil; Fluorouracil
- Indications Anal intraepithelial neoplasia
- Focus Therapeutic Use
- 19 Jan 2024 Planned End Date changed from 3 May 2024 to 21 May 2024.
- 21 Sep 2023 Planned End Date changed from 1 Sep 2025 to 3 May 2024.
- 21 Sep 2023 Planned primary completion date changed from 14 May 2024 to 15 Nov 2023.